Vorsetuzumab mafodotin (SNG-75) is an IDC directed against CD70 antigen conjugated to monomethyl auristatin F (MMAF) which was tested in a phase I trial (NCT01015911) in relapsed/refractory non-Hodgkin lymphoma and metastatic clear cell renal cell carcinoma. This evidence concerns the gene CD70 and clear cell renal carcinoma.